Skip to main content

Table 3 Grade 3 to 4 adverse events of interest

From: Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review

AEs

I 2

OR

95 % CI

P value

Anemia

0.0 %

1.02

0.83–1.24

0.883

Thrombocytopenia

39.2 %

1.06

0.74–1.51

0.771

Leucopenia

66.1 %

1.24

0.73–2.10

0.433

Neutropenia

85.8 %

1.33

0.88–2.01

0.179

Febrile neutropenia

67.2 %

1.34

0.68–2.67

0.401

Hypokalemia

38.1 %

1.09

0.81–1.47

0.586

Rash

0.0 %

21.84

6.81–70.02

<0.001*

Hand-foot syndrome

37.6 %

1.75

1.22–2.50

0.002*

Stomatitis

42.8 %

2.08

1.23–3.51

0.006*

Nausea

21.6 %

0.94

0.73–1.21

0.639

Vomit

0.3 %

0.99

0.79–1.25

0.944

Abdominal pain

0.0 %

1.10

0.47–2.57

0.821

Diarrhea

14.1 %

2.40

1.88–3.06

<0.001*

Constipation

0.0 %

0.27

0.08–0.91

0.034*

Decreased appetite

0.0 %

1.13

0.88–1.46

0.342

Fatigue

0.0 %

1.55

1.21–2.00

0.001*

Neuropathy

62.8 %

0.76

0.24–2.41

0.636

Any adverse events

86.8 %

1.53

0.98–2.40

0.062

  1. *P < 0.005, There were statistically significant differences between the two arms